Teva Pharmaceutical Industries (NYSE:TEVA) shares continued gains for seven straight sessions, as the stock closed 1% higher at $16.59 on Tuesday.
The Israeli drugmaker gained about 5% in the preceding six sessions. The stock has lost more than 25% so far this year, compared to the over 8% rise in the broader S&P 500 Index.
TEVA is down 0.7% over the past month. The stock closed 0.3% higher on Monday at $16.42.
Looking at Seeking Alpha’s Quant Rating, TEVA has a Hold rating with a score of 3.12 out of 5. The company received A- in the prospect of profitability, while it got an F for growth factor.
Turning to the Wall Street community, 10 analysts gave TEVA a Buy and above, one analyst has given the stock a Hold recommendation, and no one recommended Sell or lower.
Seeking Alpha analysts are bullish and see the stock as a Buy.
Last month, Teva missed the consensus for revenue with its Q2 2025 results, as its branded medications failed to offset headwinds to its generics business.
However, TEVA’s innovative product portfolio outperformed, with the company’s movement disorder therapy, Austedo, adding $498M in the U.S. and from international markets, and its migraine therapy Ajovy generating $155M globally with ~34% YoY growth.
“The company is delivering better results, raising guidance and slowly changing the narrative but most investors still don’t buy it. I think this is a setup where patient investors can get in before the crowd catches on,” noted Seeking Alpha analyst Motti Sapir.
Another Seeking Alpha analysis by ALLKA Research said that the company “continues to demonstrate resilience in a rather difficult time for the healthcare sector, including through the implementation of the “Pivot to Growth” strategy, as well as strengthening its position in the CNS therapeutics market due to Austedo, Ajovy, and Uzedy.”